Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.
Edwards’ technologies are categorized into business units including, heart valve therapy, critical care, cardiac surgery systems and vascular, as well as transcatheter heart valves designed for non-surgical valve replacement.
Transcatheter aortic valve implantation (TAVI) enables multi-disciplinary heart teams to replace a patient's diseased aortic valve without traditional open-heart surgery and while the heart continues to beat - avoiding the need for cardiopulmonary bypass.
In Europe, Edwards SAPIEN transcatheter heart valves have been commercially available since 2007, and the next generation Edwards SAPIEN XT valve was approved in 2010. In November 2011, the Edwards SAPIEN valve became the first commercially approved transcatheter device enabling aortic valve replacement in the United States.